ClinicalTrials.gov
ClinicalTrials.gov Menu

BMN 110 US Expanded Access Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01858103
Recruitment Status : Approved for marketing
First Posted : May 21, 2013
Last Update Posted : April 2, 2014
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical

May 15, 2013
May 21, 2013
April 2, 2014
 
BMN 110 US Expanded Access Program

The Expanded Access Program (EAP) is an open-label, multicenter program to:

  1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available
  2. Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA

Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.

Not Provided
Expanded Access
Drug: BMN 110
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Approved for marketing
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
 
 
NCT01858103
BioMarin Pharmaceutical
BioMarin Pharmaceutical
Not Provided
Not Provided
BioMarin Pharmaceutical
March 2014